vs

Side-by-side financial comparison of Axon Enterprise (AXON) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $796.7M, roughly 1.9× Axon Enterprise). Steris runs the higher net margin — 12.9% vs 0.3%, a 12.5% gap on every dollar of revenue. On growth, Axon Enterprise posted the faster year-over-year revenue change (38.9% vs 9.2%). Steris produced more free cash flow last quarter ($199.5M vs $155.4M). Over the past eight quarters, Axon Enterprise's revenue compounded faster (31.5% CAGR vs 15.8%).

Axon Enterprise, Inc. is an American company based in Scottsdale, Arizona, that develops weapons and technology products for military, law enforcement, and civilians.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

AXON vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.9× larger
STE
$1.5B
$796.7M
AXON
Growing faster (revenue YoY)
AXON
AXON
+29.8% gap
AXON
38.9%
9.2%
STE
Higher net margin
STE
STE
12.5% more per $
STE
12.9%
0.3%
AXON
More free cash flow
STE
STE
$44.1M more FCF
STE
$199.5M
$155.4M
AXON
Faster 2-yr revenue CAGR
AXON
AXON
Annualised
AXON
31.5%
15.8%
STE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
AXON
AXON
STE
STE
Revenue
$796.7M
$1.5B
Net Profit
$2.7M
$192.9M
Gross Margin
57.9%
43.8%
Operating Margin
-6.3%
18.3%
Net Margin
0.3%
12.9%
Revenue YoY
38.9%
9.2%
Net Profit YoY
-98.0%
11.2%
EPS (diluted)
$0.02
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXON
AXON
STE
STE
Q4 25
$796.7M
$1.5B
Q3 25
$710.6M
$1.5B
Q2 25
$668.5M
$1.4B
Q1 25
$603.6M
$1.5B
Q4 24
$573.4M
$1.4B
Q3 24
$544.3M
$1.3B
Q2 24
$504.1M
$1.3B
Q1 24
$460.7M
$1.1B
Net Profit
AXON
AXON
STE
STE
Q4 25
$2.7M
$192.9M
Q3 25
$-2.2M
$191.9M
Q2 25
$36.1M
$177.4M
Q1 25
$88.0M
$145.7M
Q4 24
$136.0M
$173.5M
Q3 24
$67.0M
$150.0M
Q2 24
$40.8M
$145.4M
Q1 24
$133.2M
$-1.4M
Gross Margin
AXON
AXON
STE
STE
Q4 25
57.9%
43.8%
Q3 25
60.1%
44.2%
Q2 25
60.4%
45.1%
Q1 25
60.6%
43.3%
Q4 24
60.5%
44.5%
Q3 24
60.8%
43.6%
Q2 24
60.3%
44.7%
Q1 24
56.4%
40.2%
Operating Margin
AXON
AXON
STE
STE
Q4 25
-6.3%
18.3%
Q3 25
-0.3%
18.2%
Q2 25
-0.2%
17.7%
Q1 25
-1.5%
14.6%
Q4 24
-2.6%
17.9%
Q3 24
4.4%
16.5%
Q2 24
6.5%
14.5%
Q1 24
3.5%
22.0%
Net Margin
AXON
AXON
STE
STE
Q4 25
0.3%
12.9%
Q3 25
-0.3%
13.1%
Q2 25
5.4%
12.8%
Q1 25
14.6%
9.8%
Q4 24
23.7%
12.7%
Q3 24
12.3%
11.3%
Q2 24
8.1%
11.4%
Q1 24
28.9%
-0.1%
EPS (diluted)
AXON
AXON
STE
STE
Q4 25
$0.02
$1.96
Q3 25
$-0.03
$1.94
Q2 25
$0.44
$1.79
Q1 25
$1.08
$1.48
Q4 24
$1.68
$1.75
Q3 24
$0.86
$1.51
Q2 24
$0.53
$1.46
Q1 24
$1.73
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXON
AXON
STE
STE
Cash + ST InvestmentsLiquidity on hand
$1.7B
$423.7M
Total DebtLower is stronger
$1.8B
$1.9B
Stockholders' EquityBook value
$3.2B
$7.2B
Total Assets
$7.0B
$10.6B
Debt / EquityLower = less leverage
0.56×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXON
AXON
STE
STE
Q4 25
$1.7B
$423.7M
Q3 25
$2.4B
$319.2M
Q2 25
$2.1B
$279.7M
Q1 25
$2.2B
$171.7M
Q4 24
$788.1M
$155.2M
Q3 24
$1.0B
$172.2M
Q2 24
$968.9M
$198.3M
Q1 24
$964.1M
$207.0M
Total Debt
AXON
AXON
STE
STE
Q4 25
$1.8B
$1.9B
Q3 25
$2.0B
$1.9B
Q2 25
$2.0B
$1.9B
Q1 25
$2.0B
$1.9B
Q4 24
$680.3M
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
AXON
AXON
STE
STE
Q4 25
$3.2B
$7.2B
Q3 25
$3.0B
$7.0B
Q2 25
$2.7B
$7.0B
Q1 25
$2.6B
$6.6B
Q4 24
$2.3B
$6.4B
Q3 24
$2.1B
$6.6B
Q2 24
$1.9B
$6.4B
Q1 24
$1.8B
$6.3B
Total Assets
AXON
AXON
STE
STE
Q4 25
$7.0B
$10.6B
Q3 25
$6.7B
$10.4B
Q2 25
$6.2B
$10.4B
Q1 25
$6.1B
$10.1B
Q4 24
$4.5B
$10.0B
Q3 24
$4.0B
$10.2B
Q2 24
$3.7B
$10.1B
Q1 24
$3.6B
$11.1B
Debt / Equity
AXON
AXON
STE
STE
Q4 25
0.56×
0.27×
Q3 25
0.66×
0.27×
Q2 25
0.73×
0.27×
Q1 25
0.79×
0.29×
Q4 24
0.29×
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXON
AXON
STE
STE
Operating Cash FlowLast quarter
$217.2M
$298.2M
Free Cash FlowOCF − Capex
$155.4M
$199.5M
FCF MarginFCF / Revenue
19.5%
13.3%
Capex IntensityCapex / Revenue
7.8%
6.6%
Cash ConversionOCF / Net Profit
79.14×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$75.1M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXON
AXON
STE
STE
Q4 25
$217.2M
$298.2M
Q3 25
$60.0M
$287.8M
Q2 25
$-91.7M
$420.0M
Q1 25
$25.8M
$260.8M
Q4 24
$250.2M
$332.8M
Q3 24
$91.3M
$250.7M
Q2 24
$82.8M
$303.7M
Q1 24
$-15.9M
$254.8M
Free Cash Flow
AXON
AXON
STE
STE
Q4 25
$155.4M
$199.5M
Q3 25
$33.4M
$201.3M
Q2 25
$-114.7M
$326.4M
Q1 25
$932.0K
$189.9M
Q4 24
$225.4M
$243.6M
Q3 24
$64.8M
$148.8M
Q2 24
$71.4M
$195.7M
Q1 24
$-32.1M
$163.3M
FCF Margin
AXON
AXON
STE
STE
Q4 25
19.5%
13.3%
Q3 25
4.7%
13.8%
Q2 25
-17.2%
23.5%
Q1 25
0.2%
12.8%
Q4 24
39.3%
17.8%
Q3 24
11.9%
11.2%
Q2 24
14.2%
15.3%
Q1 24
-7.0%
14.6%
Capex Intensity
AXON
AXON
STE
STE
Q4 25
7.8%
6.6%
Q3 25
3.7%
5.9%
Q2 25
3.4%
6.7%
Q1 25
4.1%
4.8%
Q4 24
4.3%
6.5%
Q3 24
4.9%
7.7%
Q2 24
2.2%
8.4%
Q1 24
3.5%
8.2%
Cash Conversion
AXON
AXON
STE
STE
Q4 25
79.14×
1.55×
Q3 25
1.50×
Q2 25
-2.54×
2.37×
Q1 25
0.29×
1.79×
Q4 24
1.84×
1.92×
Q3 24
1.36×
1.67×
Q2 24
2.03×
2.09×
Q1 24
-0.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXON
AXON

Software And Sensors Segment$342.5M43%
TASER Devices Professional$264.2M33%
Personal Sensors$109.1M14%
Platform Solutions$80.9M10%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons